At Debiopharm, every step we take is guided by one purpose: Improving the lives of people affected by cancer and infectious diseases. As a privately-owned Swiss biopharmaceutical company, we're driven by science, but above all, by the people behind every treatment - the patients and their families. Through our unique "development only" model, we bring forward promising therapies and transform them into treatments that can reach those who need them most, faster.
If you're ready to make a real impact - this is your moment.
We are currently looking for a motivated and collaborative professional to join our Clinical Safety & Pharmacovigilance team based at our Headquarters in Lausanne, Switzerland as
In this role, you will actively manage and evaluate Safety Data for products in development, working under the guidance of the Executive Safety Physician or the Head of Clinical Safety.
Requirements
Your Mission
More than a checklist of skills, we’re looking for someone who shares our commitment to science with purpose.
Your profile
Benefits
What we Offer:
What to Expect in the Recruitment Process:
If your application is selected, you’ll be invited to interviews with Talent Acquisition and the Hiring Manager via Teams, followed by a panel interview and reference checks. Communication is handled via Workable—check your spam folder for emails from *@outbound.workable.com.
Please contact our HR Department prior to submitting any profiles. We cannot accept unsolicited applications from agencies or recruiters.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe.
Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections.
Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®
If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!